Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
Narjoz C, Cessot A, Thomas-Schoemann A, Golmard JL, Huillard O, Boudou-Rouquette P, Behouche A, Taieb F, Durand JP, Dauphin A, Coriat R, Vidal M, Tod M, Alexandre J, Loriot MA, Goldwasser F, Blanchet B. Narjoz C, et al. Among authors: goldwasser f. Invest New Drugs. 2015 Feb;33(1):257-68. doi: 10.1007/s10637-014-0178-2. Epub 2014 Oct 25. Invest New Drugs. 2015. PMID: 25344452 Clinical Trial.
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.
Raymond E, Alexandre J, Faivre S, Goldwasser F, Besse-Hammer T, Gianella-Borradori A, Jego V, Trandafir L, Rejeb N, Awada A. Raymond E, et al. Among authors: goldwasser f. Invest New Drugs. 2014 Feb;32(1):94-103. doi: 10.1007/s10637-013-9950-y. Epub 2013 Mar 29. Invest New Drugs. 2014. PMID: 23539344 Clinical Trial.
Soluble VEGFR-1: a new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?).
Thomas-Schoemann A, Blanchet B, Boudou-Rouquette P, Golmard JL, Noé G, Chenevier-Gobeaux C, Lebbe C, Pages C, Durand JP, Alexandre J, Goldwasser F, Guibourdenche J, Vidal M. Thomas-Schoemann A, et al. Among authors: goldwasser f. J Clin Pharmacol. 2015 Apr;55(4):478-9. doi: 10.1002/jcph.429. Epub 2014 Dec 30. J Clin Pharmacol. 2015. PMID: 25401221 No abstract available.
Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.
Carton E, Noe G, Huillard O, Golmard L, Giroux J, Cessot A, Saidu NE, Peyromaure M, Zerbib M, Narjoz C, Guibourdenche J, Thomas A, Vidal M, Goldwasser F, Blanchet B, Alexandre J. Carton E, et al. Among authors: goldwasser f. Eur J Cancer. 2017 Feb;72:54-61. doi: 10.1016/j.ejca.2016.11.027. Epub 2016 Dec 24. Eur J Cancer. 2017. PMID: 28027516
Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R, Preta LH, Joste V, Curis E, Huillard O, Jouinot A, Narjoz C, Thomas-Schoemann A, Bellesoeur A, Tiako Meyo M, Quilichini J, Desaulle D, Nicolis I, Cessot A, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Cohen R, et al. Among authors: goldwasser f. Br J Clin Pharmacol. 2019 Jun;85(6):1227-1238. doi: 10.1111/bcp.13849. Epub 2019 Jan 30. Br J Clin Pharmacol. 2019. PMID: 30701582 Free PMC article.
340 results